Pathologic Findings from the National Surgical Adjuvant Breast and Bowel Project: Twelve-Year Observations Concerning Lobular Carcinoma In Situ

Cancer

Volumn 100, Issue 2, 2004, Pages 238-244

  Fisher, Edwin R ^a,b   Land, Stephanie R ^c,d   Fisher, Bernard ^e   Mamounas, Eleftherios ^f   Gilarski, Linda ^c   Wolmark, Norman ^e  

^a UPMC Cancer Pavilion   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c Biostatistical Center   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e Natl Surg Adjuv Breast Pathol C   (United States)

^f Aultman Cancer Center   (United States)

Author keywords

Breast carcinoma; Clinicopathology; Lobular carcinoma in situ; Recurrence

Indexed keywords

UVOMORULIN;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBULAR CARCINOMA IN SITU; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FOLLOW-UP STUDIES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL;

EID: 0346093904     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11883     Document Type: Article

References (36)

1. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78:1403-1416.
2. Hutter RV, Foote FW. Lobular carcinoma in situ: long-term follow-up. Cancer. 1969;24:1081-1085.
3. Akashi-Tanaka S, Fukutomi T, Nanasawa T, Matuso K, Hasegawa T, Tsuda H. Treatment of non-invasive carcinoma: fifteen year results at the National Cancer Center Hospital in Tokyo. Breast Cancer. 2000;7:341-344.
4. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Anderson JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62:197-210.
5. Goldstein NS, Kestin LL, Vicini FA. Clinical pathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer. 2001;92:738-747.
6. Fisher ER. Pathological considerations relating to the treatment of intraductal carcinoma (duct carcinoma in situ) of the breast. A critical review. CA Cancer J Clin. 1997;47:52-64.
7. Jacobs TW, Pliss N, Kouria G, Schnitt SH. Carcinoma in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol. 2001;25:229-236.
8. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol. 2001;115:534-542.
9. Acs G, Lawton TS, Rebbeck TR, LiVolsi VA, Shang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115:85-98.
10. Tavassoli FA. Lobdular neoplasia. In: Tavassoli FA. Pathology of the breast, 2nd edition. New York: Elsevier, 1999;373-400.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
12. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232-1239.
13. Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast: long-term follow-up. Cancer. 1974;34:554-563.
14. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-129.
15. Schnitt SJ, Morrow M. Lobular carcinoma in situ: current concepts and controversies. Semin Diagn Pathol. 1999;16 205-223.
16. Fisher ER, Sass R, Fisher B, Gregorio RM, Brown R, Wickerham L. Pathologic findings from the National Surgical Adjuvant Breast Project: Protocol VI. Relation of local breast recurrence to multicentricity. Cancer. 1986;57:1717-1724.
17. Fisher ER, Dignam J, Tan-Chiu E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP): eight-year update of Protocol B-17. Cancer. 1999;86:429-438.
18. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737-769.
19. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinoma. Am J Pathol. 1993;143:1731-1742.
20. Fisher ER, Gregorio RM, Redmond C. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol. 1977;8:679-683.
21. Fisher ER, Gregorio RM, Fisher B. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4). Cancer. 1975;36:1-85.
22. Lishman SC, Lakhani SR. Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. Histopathology. 1999;35:195-200.
23. Fisher ER, Fisher B. Lobular carcinoma of the breast: an overview. Ann Surg. 1977;17:258-264.
24. Gump FE, Kinne D, Schwartz GF. Current treatment for lobular carcinoma in situ. Ann Surg Oncol. 1998;5:33-36.
25. Bear HD, Carter WH Jr., Grimes MM. Despite limited data, coexisted lobular carcinoma in situ should not be a contraindication to breast conservation for women with invasive breast cancer. Cancer. 2000;88:982-983.
26. Moran M, Haffty BG. Lobular carcinoma in situ as a component of breast cancer: the long term outcome in patients treated with breast conversation therapy. Int J Radiat Oncol Biol Phys. 1998;40:353-358.
27. Abner AL, Connolly JL, Redit A, et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer. 2000;88:1072-1077.
28. Sasson AR, Fowble B, Hanlon HL, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with Stage I and II breast carcinoma treated with conservative surgery and radiation. Cancer. 2001;91:1862-1869.
29. Shin SV, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med. 2002;126:697-701.
30. O'Driscoll D, Britton P, Bobrow GC, Wishart GC, Sinnatamby R, Warren R. Lobular carcinoma in situ on core biopsy-what is the clinical significance? Clin Radiol. 2001;56:216-220.
31. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology. 2001;218:503-509.
32. Renshaw AA, Cartagena N, Derhagopia RP, Gould EW. Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. Am J Clin Pathol. 2002;117:797-799.
33. Simmons RM, Osborne MP. The evaluation of high risk and pre-invasive breast lesions and the decision process for follow-up and surgical intervention. Surg Oncol. 1999;8:55-65.
34. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol. 1999;173:291-299.
35. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. Cancer. 2002;95:681-695.
36. Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.